S protein mutant of novel coronavirus variant strain and genetically engineered mRNA (messenger ribonucleic acid) and vaccine composition thereof
A plurality of amino acid residues are mutated into proline in C-terminal amino acid of an extracellular structural domain of spike protein (S protein) of a novel coronavirus variant strain, an S protein mutant with a stable conformation trimer is provided, and mRNA for coding the S protein mutant and a carrier capable of preparing the mRNA through in-vitro transcription are constructed. The S protein mutant, and mRNA (including further optimized mRNA) encoding the same, can be used to induce an immune response against a novel coronavirus in a subject, thereby preventing and/or treating a disease or condition associated with a novel coronavirus infection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 15. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
JIANG JUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-15, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117229371 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000287180 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000287180 | ||
| 003 | DE-627 | ||
| 005 | 20240322143130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000287180 | ||
| 035 | |a (EPA)CN117229371 | ||
| 035 | |a (EPA)89097211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a JIANG JUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a S protein mutant of novel coronavirus variant strain and genetically engineered mRNA (messenger ribonucleic acid) and vaccine composition thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-15, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 | ||
| 520 | |a A plurality of amino acid residues are mutated into proline in C-terminal amino acid of an extracellular structural domain of spike protein (S protein) of a novel coronavirus variant strain, an S protein mutant with a stable conformation trimer is provided, and mRNA for coding the S protein mutant and a carrier capable of preparing the mRNA through in-vitro transcription are constructed. The S protein mutant, and mRNA (including further optimized mRNA) encoding the same, can be used to induce an immune response against a novel coronavirus in a subject, thereby preventing and/or treating a disease or condition associated with a novel coronavirus infection. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XIN QI |4 aut | |
| 700 | 0 | |a WANG XITING |4 aut | |
| 700 | 0 | |a LIN YAOXIN |4 aut | |
| 700 | 0 | |a LI SHIYOU |4 aut | |
| 700 | 0 | |a WANG HAO |4 aut | |
| 700 | 0 | |a WU LEI |4 aut | |
| 700 | 0 | |a WANG LINA |4 aut | |
| 700 | 0 | |a LUO XIAOMIN |4 aut | |
| 700 | 0 | |a ZHANG XINYUE |4 aut | |
| 700 | 0 | |a BAI XUEJIAO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89097211/publication/CN117229371A1?q=CN117229371 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 15 |c 12 | ||